AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06700603
Drug: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
Trial: NCT05121779
Drug: 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
Trial: NCT05121779
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
Trial: NCT04807634
Drug: Intravenous Lipid Emulsion (Intralipid 20%)
RxNorm normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
Trial: NCT05596097
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
Trial: NCT06631287
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
Trial: NCT06226532
Drug: lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
Trial: NCT06226532
Drug: Intravenous Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
Trial: NCT05744219
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active drug
Trial: NCT05217901
Drug: 14C-labeled ASP0367
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT05198349
Drug: M1069
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
Trial: NCT06036446
Drug: Vaginal Suppository Progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
Trial: NCT05503667
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib 80 mg/day for 16 weeks
Trial: NCT05503667
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 400 mg/4 weeks i.v. for 4 times
Trial: NCT04514302
Drug: Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)
RxNorm normalized name: Crotalidae immune F(ab')2 (equine)
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
Trial: NCT05974267
Drug: Pyronaridine
RxNorm normalized name: Pyronaridine
DrugBank: Pyronaridine (DB12975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
Trial: NCT05974267
Drug: Atovaquone-Proguanil
RxNorm normalized name: atovaquone-proguanil
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
Trial: NCT05227690
Drug: CVL-231 10 mg
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL-231 10 mg, oral (tablet), once per day for 6 weeks
Trial: NCT05227690
Drug: Required CVL-231 30 mg
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL-231 30 mg, oral (tablet), once per day for 6 weeks
Trial: NCT06569680
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg
Trial: NCT04730973
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
Trial: NCT06232707
Drug: Alnuctamab
RxNorm normalized name: Alnuctamab
DrugBank: Alnuctamab (DB17194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06232707
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06232707
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06232707
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06232707
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06232707
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06649214
Drug: Olanzapine-samidorphan；
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
Trial: NCT06649214
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
Trial: NCT06650540
Drug: Levofloxacin Plus Metronidazole Suppositories
RxNorm normalized name: metronidazole Rectal Suppository
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
Trial: NCT05416125
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vyvanse treatment
Trial: NCT04710576
Drug: Axatilimab
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
Trial: NCT05925309
Drug: Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
Trial: NCT05146700
Drug: Restrictive oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
Trial: NCT05146700
Drug: Liberal oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
Trial: NCT05027425
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg IV, Q4W
Trial: NCT05027425
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg IV, 1 dose on day 1 of only the first cycle
Trial: NCT05462613
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: - Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.
Trial: NCT05462613
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg orally and daily during two months
Trial: NCT05462613
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
Trial: NCT06582888
Drug: Varenicline Tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline (target dose 1mg twice daily)
Trial: NCT06084338
Drug: Pluvicto
RxNorm normalized name: Pluvicto
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA targeted radiopharmaceutical therapy
Trial: NCT03941132
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.
Trial: NCT05303727
Drug: Anti Thymocyte Globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
Trial: NCT05303727
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day for 5 days
Trial: NCT05303727
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg/m2/day for 3 days in cord blood stem cell transplantation
Trial: NCT05303727
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
Trial: NCT05303727
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
Trial: NCT05303727
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
Trial: NCT05986084
Drug: Cabotegravir Injection [Apretude]
RxNorm normalized name: cabotegravir Injection [Apretude]
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05303727
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
Trial: NCT05221502
Drug: Delamanid + Bedaquiline + OPC-167832 10 mg
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (10 mg QD) for 17 weeks
Trial: NCT05221502
Drug: Delamanid + Bedaquiline + OPC-167832 30 mg
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (30 mg QD) for 17 weeks
Trial: NCT05221502
Drug: Delamanid + Bedaquiline + OPC-167832 90 mg
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
Trial: NCT05221502
Drug: RHEZ
RxNorm normalized name: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
Trial: NCT05303727
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
Trial: NCT05303727
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/kg/dose every 12 hours
Trial: NCT05103410
Drug: ARIPiprazole 30 MG
RxNorm normalized name: aripiprazole 30 MG
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
Trial: NCT05509153
Drug: NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
Trial: NCT00334477
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04900363
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive AK112 intravenously.
Trial: NCT06477406
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
Trial: NCT04941443
Drug: Methadone Pill
RxNorm normalized name: methadone Pill
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
Trial: NCT06653517
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.
Trial: NCT06653517
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.
Trial: NCT02161939
Drug: Daclatasvir (BMS-790052)
RxNorm normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02161939
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05410730
Drug: SHR-1501
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
Trial: NCT05411575
Drug: Plerixafor 20 MG/ML [Mozobil]
RxNorm normalized name: plerixafor 20 MG/ML [Mozobil]
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
Trial: NCT05351541
Drug: Psilocybin therapy with Zolpidem and Modafinil
RxNorm normalized name: Modafinil
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
Trial: NCT05351541
Drug: Psilocybin therapy with Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
Trial: NCT05351541
Drug: Psilocybin therapy with Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
Trial: NCT05351541
Drug: Psilocybin therapy with Placebo
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-30 mg (oral administration), and placebo (oral administration)
Trial: NCT05418309
Drug: Tislelizumab Nab paclitaxel
RxNorm normalized name: Tislelizumab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Trial: NCT05402371
Drug: Rencofilstat
RxNorm normalized name: Rencofilstat
DrugBank: Rencofilstat (DB18246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rencofilstat soft gel capsule
Trial: NCT05934669
Drug: Intranasal Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
Trial: NCT05934669
Drug: Intranasal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See above
Trial: NCT05934669
Drug: Intranasal Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See above
Trial: NCT06539143
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Paracervical Block with lidocaine for manual vacuum aspiration
Trial: NCT04772742
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab - 100 mg, solution for infusion